• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Torntpharm Share Price

    Torrent Pharmaceuticals Share PriceTorrent Pharmaceuticals

    Large Cap 7.6k Result
    ₹2,126.55
    34.7 (1.66%)
    • Advice
    • Hold
    As on 30 November, 2023 | 20:47 BSE: 500420 NSE: TORNTPHARMISIN: INE685A01028
    Bonus

    Torrent Pharmaceuticals Performance

    Day Range

    • Low 2,077.85
    • High 2,140.00
    ₹ 2,126.55

    52 Week Range

    • Low 1,445.55
    • High 2,145.00
    ₹ 2,126.55
    • Open Price2,091.85
    • Previous Close2,091.85
    • Volume529836

    Start SIP in Torrent Pharmaceuticals

    Start SIP

    Torrent Pharmaceuticals Share Price

    • Over 1 Month 10.16%
    • Over 3 Month 8.79%
    • Over 6 Month 24.1%
    • Over 1 Year 28.11%

    Torrent Pharmaceuticals Key Statistics

    P/E Ratio 54
    PEG Ratio 0.8
    Market Cap Cr 71,972
    Price to Book Ratio 11.6
    EPS 30.2
    Dividend 1
    Relative Strength Index 70.19
    Money Flow Index 58.92
    MACD Signal 45.7
    Average True Range 43.08

    Torrent Pharmaceuticals F&O

    Torrent Pharmaceuticals Futures
    Torrent Pharmaceuticals Option Chain

    Torrent Pharmaceuticals Investment Rating

    • Master Rating:

    • Torrent Pharmaceuticals has an operating revenue of Rs. 10,233.00 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 19% is great, ROE of 20% is exceptional. The company has a reasonable debt to equity of 40%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 16% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 76 which is a FAIR score but needs to improve its earnings, a RS Rating of 52 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Torrent Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,1462,1211,9201,8571,9281,9331,662
    Operating Expenses Qtr Cr 1,4101,3841,3421,2721,3081,2681,179
    Operating Profit Qtr Cr 736737578585620665483
    Depreciation Qtr Cr 192183182156156149147
    Interest Qtr Cr 77909491625152
    Tax Qtr Cr 155152109124141167124
    Net Profit Qtr Cr 327323219229272327221
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 7,7776,946
    Operating Expenses Annual Cr 5,2304,642
    Operating Profit Annual in Cr 2,4652,101
    Depreciation Cr 672602
    Interest Annual Cr 298236
    Tax Annual Cr 526475
    Net Profit Annual Cr 1,051991
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 2,2652,140
    Cash from Investing Activity Annual Cr -2,384-160
    Cash from Financing Annual Activity Cr 81-1,977
    Net Cash Flow Annual Cr -383
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 6,4566,345
    Fixed Assets Annual Cr 8,6706,819
    Total Non Current Assets Annual Cr 8,9457,093
    Total Current Assets Annual Cr 3,9274,060
    Total Assets Annual Cr 12,87211,153
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 191375
    ROE Annual % 1616
    ROCE Annual % 2020
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3334
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,6602,5912,4912,4912,2912,3472,131
    Operating Expenses Qtr Cr 1,8351,8001,7641,7671,6121,6351,570
    Operating Profit Qtr Cr 825791727724679712561
    Depreciation Qtr Cr 201191196193163155162
    Interest Qtr Cr 91103107102695557
    Tax Qtr Cr 17315314613615117831
    Net Profit Qtr Cr 386378287283312354-118
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 9,6658,705
    Operating Expenses Annual Cr 6,7786,077
    Operating Profit Annual in Cr 2,8422,431
    Depreciation Cr 707662
    Interest Annual Cr 333255
    Tax Annual Cr 602449
    Net Profit Annual Cr 1,245777
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 2,3681,803
    Cash from Investing Activity Annual Cr -2,415-197
    Cash from Financing Annual Activity Cr 77-1,781
    Net Cash Flow Annual Cr 30-175
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 6,1985,953
    Fixed Assets Annual Cr 8,5496,793
    Total Non Current Assets Annual Cr 9,6837,805
    Total Current Assets Annual Cr 5,3295,295
    Total Assets Annual Cr 15,01213,100
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 183352
    ROE Annual % 2013
    ROCE Annual % 2323
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3031
    Invest in Torrent Pharmaceuticals

    Torrent Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹2,126.55
    34.7 (1.66%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹2,056.15
    • 50 Day
    • ₹1,991.26
    • 100 Day
    • ₹1,932.15
    • 200 Day
    • ₹1,836.98
    • 20 Day
    • ₹2,056.66
    • 50 Day
    • ₹1,956.07
    • 100 Day
    • ₹1,950.02
    • 200 Day
    • ₹1,797.85

    Torrent Pharmaceuticals Resistance and Support

    PIVOT
    ₹2,114.81
    Resistance
    First Resistance 2,151.75
    Second Resistance 2,176.95
    Third Resistance 2,213.90
    RSI 70.19
    MFI 58.92
    MACD Single Line 45.70
    MACD 45.43
    Support
    First Resistance 2,089.60
    Second Resistance 2,052.65
    Third Resistance 2,027.45

    Torrent Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 532,164 29,540,424 55.51
    Week 304,012 15,200,575 50
    1 Month 260,476 13,195,690 50.66
    6 Month 424,223 23,616,467 55.67

    Torrent Pharmaceuticals Result Highlights

    Torrent Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Torrent Pharmac is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 7695.20 Cr. and Equity Capital is Rs. 169.23 Cr. for the Year ended 31/03/2023. Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126.
    Market Cap 72,312
    Sales 8,044
    Shares in Float 9.81
    No of funds 680
    Yield 1.05
    Book Value 11.2
    U/D Vol ratio 0.9
    LTDebt / Equity 36
    Alpha 0.09
    Beta 0.43

    Torrent Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 71.25%71.25%71.25%71.25%
    Mutual Funds 5.32%5.59%6.37%6.23%
    Insurance Companies 1.85%1.99%1.87%1.99%
    Foreign Portfolio Investors 13.15%12.85%12.04%12.09%
    Financial Institutions/ Banks
    Individual Investors 4.25%4.37%4.47%4.72%
    Others 4.18%3.95%4%3.72%

    Torrent Pharmaceuticals Management

    Name Designation
    Mr. Sudhir Mehta Chairman Emeritus
    Mr. Samir Mehta Executive Chairman
    Mr. Aman Samir Mehta Whole Time Director
    Mr. Jinesh Shah Director - Operations
    Dr. Maurice Chagnaud Independent Director
    Mr. Manish Mahendra Choksi Independent Director
    Mr. Shailesh Haribhakti Independent Director
    Mr. Haigreve Khaitan Independent Director
    Ms. Ameera Shah Independent Director
    Ms. Nayantara Bali Independent Director

    Torrent Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Torrent Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-10-23 Quarterly Results
    2023-08-07 Quarterly Results
    2023-05-30 Audited Results & Final Dividend
    2023-01-25 Quarterly Results & Interim Dividend
    2022-10-21 Quarterly Results
    Date Purpose Remarks
    2023-06-23 FINAL Rs.8.00 per share(160%)Final Dividend
    2023-02-03 INTERIM Rs.14.00 per share(280%)Interim Dividend
    2022-06-06 FINAL Rs.8.00 per share(160%)Final Dividend
    2022-06-06 SPECIAL Rs.15.00 per share(300%)Special Dividend
    2022-02-03 INTERIM Rs.25.00 per share(500%)Interim Dividend
    Date Purpose Remarks
    2022-07-11 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 5/-.

    Torrent Pharmaceuticals MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 63,981
    ICICI Prudential Balanced Advantage Fund Growth 49,871
    Mirae Asset Large Cap Fund Regular Growth 34,377
    Kotak Emerging Equity Scheme Growth 33,700
    Kotak Equity Arbitrage Fund Growth 28,958

    About Torrent Pharmaceuticals

    Torrent Pharmaceuticals Limited (TPL) is one of India’s leading pharmaceutical companies, with a strong presence in research and development, manufacturing and marketing. In terms of oncology specialty therapies, TPL is one of India's leading pharma companies. The specialties business includes three major therapeutic areas: Cancer Chemotherapy, Cardiology, and Anti-Infectives. TPL has established itself as a leader in its field by providing affordable medicines to patients across India. In addition to cancer care, TPL is also recognized for its anti-infective products, such as Ciprofloxacin which are widely used in treating bacterial infections. 

    Business Verticals

    Torrent Pharmaceuticals is a global specialty pharmaceutical and OTC medicines player. The Company has two divisions: Pharmaceuticals and Consumer Healthcare (OTC). 

    Torrent's Pharmaceuticals division consists of three major therapeutic areas: Cardiovascular, Central Nervous System (CNS) and Metabolic Diseases. Its products include branded formulations for treating cardiovascular diseases, central nervous system disorders and metabolic diseases. They are available as tablets, capsules, injectables and syrups. 

    It also offers active pharmaceutical ingredients (APIs), which other companies use to manufacture their drugs. In addition, Torrent's Pharmaceuticals markets its consumer healthcare products through its direct sales force in India. Torrent has manufacturing facilities across India and exports its products to over 80 countries worldwide.

    Milestones

    1959 - Shri U. N. Mehta ventured in the pharmaceutical  industry.

    1971 - Trinity Laboratories was renamed as Torrent Pharmaceuticals Limited.

    1980 - The first manufacturing facility was established in Ahmedabad at Vatva.

    1983 - Torrent Pharmaceuticals enters international markets with the first export order to the USSR.

    1984
    Torrent Laboratories Limited wins Chemexcil Export Award.
    Torrent Laboratories Limited received the Udyog Ratna Award.

    1985
    After demonstrating exceptional export performance, Torrent Laboratories Limited is honoured with the IMC Golden Jubilee Endowment Award.
    Torrent Exports Limited wins the Gujarat Government export award.
    IDMA awarded Torrent Laboratories Limited the Quality Excellence Award.

    1986
    Torrent Laboratories Limited wins the Chemexcil Export Award third time in a row.
    The IDMA Quality Excellence Award was presented to Torrent Laboratories Limited.
    Torrent Exports Limited wins the Gujarat Government export award again.

    1987
    Torrent Laboratories Limited wins the Chemexcil Export Award for the fourth consecutive year.
    The Gujarat government awarded Torrent Exports Limited an export award for the third time.

    1988 - Torrent Laboratories Limited wins the Chemexcil Export Award for the fifth consecutive year.

    1989
    Torrent Laboratories establish their second manufacturing plant.
    Chemexcil Trishul Award for Highest Pharma Exports awarded to Torrent Exports Limited.
    Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award.

    1990
    Torrent Exports Limited wins the National Export Award.
    Torrent Pharmaceuticals Ltd wins the International Friendship's Pride of Asia International award for excellence in pharmaceutical products.

    1992 - Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award for the second time.

    1995 - The Torrent Gujarat Biotech Limited plant gets commissioned.

    1999
    Torrent Pharmaceuticals Ltd gets revamped. Three new divisions, Prima, Vista, and Psycan, are formed.
    Torrent Research Center receives its first patent for a new chemical entity.
    Torrent Exports Limited wins the GCCI Export Recognition Award
    Torrent Pharma wins the IDMA Gold Trophy.

    2000
    Torrent Research Center is awarded the OECD Standards of Good Laboratory Practices Certificate by the Dutch Health Ministry.
    The Indrad Plant gets the ISO 9001:2000 certification.

    2001
    In terms of Return on Capital Employed, Torrent Pharma was ranked among the top ten Indian companies (ET - BCG Study Feb - 2001).
    Torrent Pharmaceuticals wins the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
    Torrent Pharma wins the IDMA Quality Excellence Award Gold Trophy for its Formulation facility. It is awarded the Silver Trophy for its API manufacturing facility as well.
    Torrent do Brasil Ltda. was founded and incorporated in Brazil.

    2002
    The AGE (Advanced Glycosylation End-products) molecule is discovered and patented.
    Torrent Pharma's Indrad Plant gets ISO 14001:1996 and OHSAS 18001:1999 certifications.
    Torrent's R&D Center with ISO/IEC 17025:1999 gets accredited by the National Accreditation Board for Testing and Calibration Laboratories for its facilities (NABL).
    Torrent Pharmaceuticals Ltd launches a new marketing division, MIND.
    Torrent Research Center develops its own Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System, and Multiparticulate / Matrix Based SR / Modified Release Formulations.

    2003
    Torrent Pharma Inc. is founded and incorporated in the United States.
    Torrent Pharmaceuticals Manufacturing Plant receives GMP certification from the European Union.
    Torrent Pharma Philippines Inc. is founded and incorporated.
    Torrent Pharma received the Gold Trophy for the IDMA Quality Excellence Award again for its formulation and API manufacturing facilities.

    2006
    The API and formulation manufacturing facilities in Indrad (Gujarat, India) receive the most coveted US FDA approval.
    South African Torrent Pharma and Pharma Dynamics (Pty) Ltd signed a Technical Agreement to supply various products.

    2007
    Indrad Plant with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System), and OHSAS 180001:1999 (Occupational Health and Safety Management System) get certified by ISOQAR, a UKAS accredited body.
    Sikkim Plant construction begins.

    2008 - The Baddi Plant gets the prestigious GMP certification from the Government of Upper Bavaria in Germany.

    2009
    Novo Nordisk commissions a dedicated formulation and packaging unit to Torrent Pharmaceuticals Ltd for exclusively manufacturing Insulin.
    AstraZeneca signed a license and supply agreement to market its products in the international market.
    Baddi Plant gets a five-star rating from the British Safety Council.

    2010
    Baddi Plant receives the OHSAS Audit 18001:2007 certification. Uganda's regulatory authority approves the Baddi Plant facility.
    An advanced facility for Stability Studies gets established at the Indrad Plant.
    Torrent Pharmaceuticals Ltd enter the field of gynaecology therapy.
    Laboratories Torrent S.A. de C.V Mexico begins its commercial operations.
    Dahej manufacturing facility construction begins.

    2011
    The Sikkim Plant begins operations.
    Torrent Research Center creates an indigenous nasal drug delivery system.
    Torrent Pharmaceuticals Ltd launches Sparsh, a dedicated division to serve the Dermatology Segment.

    2012
    The Indrad Plant is bestowed with the Sword of Honor for Occupational Health and Safety by the British Safety Council.
    Torrent Research Center discovers the Topical Foams system.

    2013 - Torrent Pharma signs a licensing agreement with Reliance Life Sciences for three biosimilars: rituximab, adalimumab, and cetuximab.

    2014
    Elder Pharma's identified Indian Branded Formulation Business in India and Nepal gets acquired by Torrent Pharmaceuticals. 
    Nephro, a dedicated division is established to exclusively serve the Nephrology Segment.
    The Dahej Plant of Torrent Pharma initiates their operations.

    2015
    10th CNBC TV18 India Business Leader Awards 2014 witnesses the victory of Torrent Pharma as the Most Promising Company of the Year.
    Torrent acquired Zyg Pharma.

    2016
    The Dahej Plant gets the USFDA certification.
    Torrent Pharmaceuticals acquires API manufacturing unit of Hyderabad-based Glochem Industries Limited.

    2017
    Torrent Pharmaceuticals acquire Unichem's domestic and Nepal operations along with its Sikkim manufacturing facility.
    Business World Magazine names them as one of the top five 'Fastest Growing Companies (Middleweights Category)'.
    Executive Chairman, is named as one of India's Most Valuable CEOs in the by Business World Magazine.
    Torrent Pharmaceuticals acquires all Novartis' Women Healthcare brands.

    2018 - Torrent makes its first overseas purchase by acquiring Bio-Pharm Inc. (BPI), based in the United States along with a US FDA-registered manufacturing facility. 

    2019 - Torrent and Glenmark sign a licensing agreement for co-marketing Remogliflozin Etabonate pan-India.

    2021
    In India, Torrent Pharma launches MSD (a trademark of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's Molnupiravir under the brand name Molnutor®.
    Torrent Pharma Signs Voluntary Licensing Agreement with Lilly to produce and distribute Baricitinib for Covid-19 in India.

    2022 
    Torrent finalizes the acquisition of Dr. Reddy's Laboratories Ltd. four brands: "Styptovit-E," "Finast," "Finast-T," and "Dynapress."
    Torrent Pharma signs a licensing agreement with Medicine Patent Pool for the production and marketing of a generic version of Pfizer's Oral COVID-19 Treatment.

    Torrent Pharmaceuticals FAQs

    What is Share Price of Torrent Pharmaceuticals ?

    Torrent Pharmaceuticals share price is ₹2,126 As on 30 November, 2023 | 20:33

    What is the Market Cap of Torrent Pharmaceuticals ?

    The Market Cap of Torrent Pharmaceuticals is ₹71972.1 Cr As on 30 November, 2023 | 20:33

    What is the P/E ratio of Torrent Pharmaceuticals ?

    The P/E ratio of Torrent Pharmaceuticals is 54 As on 30 November, 2023 | 20:33

    What is the PB ratio of Torrent Pharmaceuticals ?

    The PB ratio of Torrent Pharmaceuticals is 11.6 As on 30 November, 2023 | 20:33

    What were the company's most recent reported sales and net income?

    Torrent Pharmaceuticals Ltd recorded a net sales of INR 8508 crores in the year ending March 2022.

    What is the future of the company's shares?

    Torrent Pharmaceuticals Ltd stock is a good option for long-term investment since the stock prices indicate a strong buying trend.

    How to buy shares of Torrent Pharmaceuticals Ltd.?

    The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.